Researchers are hoping to get into the clinic in the next three to 5 years with a self-assembling nanoparticle that targets tumors. The idea behind the technology is to make cancer cells more identifiable when using magnetic resonance imaging screening.
Once known as a serial acquirer, Danaher broke its big acquisition drought with the addition of Siemen's clinical microbiology unit to its Beckman Coulter division. The price was not disclosed, but company officials described it as the largest deal in two years during the quarterly earnings call on the heels of the July 17 announcement.
Conventional imaging methods don't work so well in the gut, the site of irritable bowel syndrome, celiac disease and Crohn's disease among others. Researchers at the University of Buffalo say they have solved the problem, albeit in animal studies.
Five senate Democrats called for the White House Office of Management and Budget to release a long-sequestered FDA draft guidance on laboratory developed tests for public comment. In a letter to OMB acting director Brian Deese, they urged him to release the proposed regulation "to ensure appropriate and efficient oversight of diagnostic tools can move forward in an open and transparent manner."
Definiens secured financing to grow its existing imaging-analysis business and to expand into tissue diagnostics. New investor Wellington Partners led the €15 million ($20.4 million) financing and joined the board.
Cell phones are indispensable for many. Now a plug-in meter that's about the size of a quarter makes it easier to track blood sugar on a mobile device. The newly launched iHealth Align is the world's smallest FDA-approved blood glucose monitor, according to its maker, iHealth.
AbbVie will have exclusive promotion rights to the sole FDA-approved point-of-care test for the hepatitis C virus, under a co-promotion agreement with OraSure Technologies, maker of the OraQuick HCV Rapid Test.
The data are an analysis of the costs paid through employer-sponsored benefits for four common outpatient services including a lipid panel, a CT scan of the head or brain, and an MRI of the lower back. It was conducted by healthcare consultancy Castlight Health.
The FDA gave de novo approval to Menlo Park-based Auxogyn's Eeva System, a fertility-enhancing diagnostic test currently available in Europe and Canada.
The FDA approved the latest version of WatchPat, a home sleep diagnostic device.